Načítá se...
Personalized radioiodine therapy for thyroid cancer patients with known disease
Radioactive iodine (RAI) (131)I is a targeted therapy for patients with RAI-avid follicular cell-derived thyroid cancer. However, the responsiveness to (131)I therapy varies among thyroid cancer patients mainly owing to differential RAI uptake and RAI radiosensitivity among patients’ lesions. A pers...
Uloženo v:
| Vydáno v: | Fac Rev |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Faculty Opinions Ltd
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8103907/ https://ncbi.nlm.nih.gov/pubmed/33977289 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12703/r/10-36 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|